Annotation of rs3025039

Genotype CC is not associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype TT.

as determined by changes in visual acuity score. [stat_test: anova, followed by permutation testing for corrected probabilities]

From Publication

Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population. Pharmacogenomics. 2012. Tian Jun et al.
PMID:22594510(opens in new window) DOI:10.2217/pgs.12.53(opens in new window)

Gene

VEGFA

Variant

rs3025039

Phenotype Category

Efficacy

Association Significance

The study reports this association is not significant

PharmGKB ID

827920081

Score
More info on scoring

-1.5

Evidence for Clinical Annotations

This annotation has been used as evidence for the following clinical annotations.

    Study Parameters

    Study type

    cohort

    Study size

    144

    Association p-value

    = 0.908

    Biogeographical group
    More info on groups

    East Asian

    Population description

    Study Cohort: Patients with neovascular age-related macular degeneration (AMD) characterized by active choroidal neovascularization (CNV) from 13 centers located throughout China.

    Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.

    History

    Loading...